登录 | 注册    微信公众号  
搜索
 >  其他蛋白>CD20 >CD0-C52H8

Cynomolgus CD20 / MS4A1 Full Length Protein, His Tag

分子别名(Synonym)

MS4A1,CD20,MS4A-1

表达区间及表达系统(Source)

Cynomolgus CD20 Full Length, His Tag (CD0-C52H8) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # M4ZHZ6-1 ).

Predicted N-terminus: Met 1

Request for sequence

蛋白结构(Molecular Characterization)

Online(Met 1 - Pro 297) M4ZHZ6-1

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 35.2 kDa. The protein migrates as 36-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5. Normally glycerol is added as protectant before lyophilization.

This product is not suitable for cell based experiments due to cytotoxicity of DDM.

DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.

DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.

If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped as sterile liquid solution with dry ice, please inquire the shipping cost.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. The product MUST be stored at -70°C or lower upon receipt;
  2. -70°C for 3 months under sterile conditions.
*The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow this link for product information.
 

电泳(SDS-PAGE)

Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) SDS-PAGE gel

Cynomolgus CD20 Full Length, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Measured by its binding ability in a functional ELISA. Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with a linear range of 1-31 ng/mL (QC tested).

Protocol

Biotinylated Human  ELISA

Measured by its binding ability in a functional ELISA. Immobilized Ofatumumab at 2 μg/mL (100 μL/well) can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with a linear range of 0.2-16 ng/mL (QC tested).

Protocol

Biotinylated Human ELISA

Immobilized Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) at 5 μg/mL (100 μL/well) can bind Biosimilar of Obinutuzumab with a linear range of 0.3-10 ng/mL (Routinely tested).

Protocol

活性(Bioactivity)-SPR

Biotinylated Human SPR

Rituximab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 5.48 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Protocol

Biotinylated Human SPR

Ofatumumab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 3.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

Protocol

 

背景(Background)

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

 

前沿进展

 
 
货号/价格
开发建议
文档
联系电话:
400-682-2521(全国)
010-57737274(北京)
021-26136428(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
techsupport@acrobiosystems.com
CD20靶点信息
英文全称:B-lymphocyte antigen CD20
中文全称:B淋巴细胞抗原CD20
种类:Homo sapiens
上市药物数量:23详情
临床药物数量:81详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定